Why geography still shapes who gets stroke treatment

A treatment that works in a trial and a treatment that reaches a patient are two different achievements. Acute stroke is the clearest case in modern medicine where the gap between them is measurable, persistent, and largely a matter of geography.

This is an explainer about that gap, written in the same spirit as the broader stroke outcomes research it draws on. It is educational and not a substitute for personal medical advice.

Two questions that get merged

Clinical research answers a question about efficacy: under study conditions, in eligible patients, does this therapy improve outcomes compared with the alternative? Health services research answers a different one: among the people who would have benefited, how many actually received it?

A therapy can succeed decisively on the first question and still fail large populations on the second. Epidemiologists keep these separate because the remedies are entirely unrelated. A disappointing efficacy result calls for better science. A disappointing access result calls for changes to systems, staffing, transport, and money.

Two acute treatments matter here, and both deserve plain definition. Intravenous thrombolysis is the administration of a drug that dissolves the clot blocking an artery in the brain. Endovascular thrombectomy is a catheter procedure in which the clot is physically removed from the vessel. The first requires a drug, a protocol, and imaging. The second requires a hospital with an angiography suite and a trained proceduralist available at the moment the patient arrives.

That difference in requirements is the whole story.

Why acute stroke is unusually sensitive to distance

Almost every therapy is somewhat sensitive to access. Acute stroke treatment is sensitive to it in an unusual way, for two structural reasons.

The first is time. Both treatments are effective within a limited window after symptoms begin, and their benefit diminishes as that window closes. The clock does not start when a patient reaches a specialist. It starts at symptom onset, which means travel time is subtracted directly from treatment benefit rather than merely delaying it. A therapy whose value decays with the clock converts distance into lost effectiveness in a way that a chronic-disease medication does not.

The second is capability concentration. Many hospitals can administer a thrombolytic drug. Far fewer can perform thrombectomy, because the procedure requires equipment and a specific kind of expertise that is expensive to maintain and, in a low-volume facility, difficult to justify. The set of hospitals that can deliver the more technically demanding treatment is therefore substantially smaller and unevenly distributed.

Transfer is the mechanism that connects these two facts, and it is not a solution so much as a trade. A patient who arrives at a hospital without thrombectomy capability may still be moved to one that has it. But the transfer itself consumes part of the treatment window. The patient may arrive eligible, or may arrive too late, and which of those happens depends heavily on where the ambulance went first.

What the published data show

The most frequently cited quantification of this gap in the United States comes from an analysis of the National Inpatient Sample, a large administrative database of hospital discharges. Researchers examined more than 790,000 stroke hospitalizations from 2012 through 2017, comparing patients treated at rural hospitals with those treated at urban hospitals. The American Heart Association summarized the findings when the work was published in Stroke.

Rural patients were about half as likely as urban patients to receive intravenous thrombolysis for clot-caused strokes, and about one third less likely to undergo thrombectomy. In-hospital mortality was 6.87 percent among rural patients and 5.82 percent among urban patients. The investigators found no improvement in the rural-urban disparity across the five-year study period.

Two features of that result deserve emphasis, and they pull in opposite directions.

The treatment-rate difference is large and hard to explain away. A twofold difference in thrombolysis delivery is not a subtle statistical artifact, and it aligns with what the structural argument above would predict.

The mortality comparison, however, must be read carefully. These are administrative discharge data. They describe an association between hospital setting and the treatment a patient received, and an association between setting and in-hospital death. They cannot by themselves establish that the setting caused the difference in survival. Patients at rural and urban hospitals may differ in stroke severity, in the presence of other conditions, in how quickly symptoms were recognized, and in how many were transferred out before dying or dying elsewhere. Each of those can move an in-hospital mortality figure without any difference in quality of care. The honest summary is that the treatment gap is well documented and the survival gap is consistently observed but not causally proven.

It also matters that these data run from 2012 to 2017. Acute stroke practice changed considerably over the following years. The figures describe a documented historical pattern, not a measurement of the current year.

What a new guideline changes, and what it does not

In January 2026 the American Heart Association and American Stroke Association published the 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke in Stroke, replacing the 2018 guideline and its 2019 update. The document's own abstract describes its key updates as including new evidence on thrombolytic choice and eligibility, on the determination of eligibility for endovascular thrombectomy, and on the management of hyperglycemia and dysphagia, along with a focused consideration of pediatric patients.

Eligibility, in other words, is one of the areas the guideline explicitly revisits.

This is exactly where the distinction between efficacy and access becomes practical rather than academic. A guideline determines who should be considered a candidate for a treatment. It does not build an angiography suite, staff it overnight, or shorten a ninety-minute drive. Guidelines define eligibility; systems of care determine delivery.

The consequence is worth stating plainly, because it is counterintuitive. When eligibility criteria change while capability remains unevenly distributed, an access gap can widen rather than narrow. Expanding the set of patients who should receive a treatment expands it everywhere on paper, but converts into delivered care only where the capability already exists. Measured as the difference between recommended and received care, the disparity can grow even as the guideline improves.

How researchers try to close the gap

Interventions aimed at this problem generally operate on the system rather than the patient. Prehospital triage and routing protocols attempt to send patients directly to a hospital that can treat them, rather than to the nearest one. Telestroke consultation connects a remote clinician to a stroke specialist in real time. Inter-facility transfer agreements attempt to make the handoff faster and more predictable.

A 2026 American Heart Association scientific statement on stroke care in rural settings, published in Stroke, examines this terrain from the perspective of nursing. It identifies telemedicine, artificial intelligence-based clinical support tools, education models, and data-driven quality improvement as principal areas of focus. It is also candid about constraints. Rural nurses face limited access to specialized education, staffing shortages, and geographic barriers. And telemedicine adoption in rural areas remains limited, the statement notes, largely because of infrastructure costs that low-volume facilities often cannot absorb.

That last point is a useful corrective to a common assumption. Telemedicine is frequently described as the obvious answer to geographic disparity. The statement's own assessment is that its adoption is constrained by the same resource limitations that produced the disparity.

Evaluating any of these programs is methodologically difficult, for a reason worth understanding. Hospitals are not randomly assigned to adopt a telestroke program. The facilities that adopt one tend to differ systematically from those that do not, in funding, in leadership, in patient volume, and in baseline quality. A study comparing adopters with non-adopters is therefore comparing two populations that differed before the intervention began, and separating the program's effect from those pre-existing differences requires careful design rather than simple comparison.

How to read a disparities study

Several questions make these studies much easier to evaluate.

• How was setting classified? Rural and urban are administrative categories with several competing definitions, and the choice affects which hospitals land in which group.
• Was case mix accounted for? Stroke severity differs across settings and drives both the treatment decision and survival. Unadjusted comparisons can attribute to geography what belongs to severity.
• Is the outcome in-hospital or longer-term? In-hospital mortality is sensitive to transfer and discharge patterns, which differ systematically between rural and urban facilities.
• What years do the data cover? Acute stroke practice changed substantially across the 2010s, and a finding from mid-decade may not describe current care.

What the evidence supports

Read in proportion, the literature supports a specific and limited set of conclusions. There is a consistent, well-documented association between hospital setting and whether a patient receives acute stroke treatment, with rural patients considerably less likely to receive either therapy. There is an accompanying difference in in-hospital survival that has been observed repeatedly but has not been shown to be caused by setting alone. And there is no published evidence that the treatment gap closed over the period studied.

The structural explanation is unusually clear for a health disparity: a time-dependent therapy delivered from a concentrated set of facilities will reach patients unevenly, and the unevenness will follow a map. That clarity is what makes it a tractable research problem rather than merely a lamentable one.

Readers interested in the underlying methods and the broader body of work may wish to explore the peer-reviewed literature directly.